Access the full text.
Sign up today, get DeepDyve free for 14 days.
B. Lawrence, B. Gustafsson, A. Chan, B. Svejda, M. Kidd, I. Modlin (2011)
The epidemiology of gastroenteropancreatic neuroendocrine tumors.Endocrinology and metabolism clinics of North America, 40 1
C. Louvet, G. Szot, Jiena Lang, Michael Lee, Nicolas Martinier, G. Bollag, Shirley Zhu, A. Weiss, J. Bluestone (2008)
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic miceProceedings of the National Academy of Sciences, 105
R. Jensen, G. Cadiot, M. Brandi, W. Herder, G. Kaltsas, P. Komminoth, J. Scoazec, R. Salazar, A. Sauvanet, R. Kianmanesh (2011)
ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor SyndromesNeuroendocrinology, 95
J. Capdevila, J. Tabernero (2011)
A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.Cancer discovery, 1 3
J. Clore, Linda Thurby-Hay (2009)
Glucocorticoid-induced hyperglycemia.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 15 5
C. Bello, M. Mulay, Xin Huang, S. Patyna, M. Dinolfo, S. Levine, A. Vugt, M. Toh, C. Baum, L. Rosen (2009)
Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of SunitinibClinical Cancer Research, 15
Mohid Khan, M. Caplin (2011)
Therapeutic management of patients with gastroenteropancreatic neuroendocrine tumours.Endocrine-related cancer, 18 Suppl 1
J. Ebos, Christina Lee, W. Cruz-Muñoz, G. Bjarnason, J. Christensen, R. Kerbel (2009)
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.Cancer cell, 15 3
James Yao, M. Pavel, A. Phan, M. Kulke, S. Hoosen, Jessica Peter, A. Cherfi, K. Öberg (2011)
Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.The Journal of clinical endocrinology and metabolism, 96 12
S. Pool, Sander Bison, S. Koelewijn, Linda Graaf, M. Melis, E. Krenning, M. Jong (2013)
mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer.Cancer research, 73 1
J. Eads, N. Meropol (2012)
A new era for the systemic therapy of neuroendocrine tumors.The oncologist, 17 3
C. Porta, S. Osanto, A. Ravaud, M. Climent, U. Vaishampayan, D. White, P. Creel, B. Dickow, P. Fischer, S. Gornell, F. Meloni, R. Motzer (2011)
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.European journal of cancer, 47 9
A. Phan (2013)
Metastatic pancreatic neuroendocrine tumors (pNET): placing current findings into perspective.Cancer treatment reviews, 39 1
Rajesh Gupta, M. Maitland (2011)
Sunitinib, Hypertension, and Heart Failure: A Model for Kinase Inhibitor-Mediated CardiotoxicityCurrent Hypertension Reports, 13
M. Kaymakcalan, Y. Je, G. Sonpavde, M. Galsky, P. Nguyen, Paul Nguyen, D. Heng, C. Richards, T. Choueiri (2013)
Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitorsBritish Journal of Cancer, 108
K. Öberg, G. Åkerström, G. Rindi, S. Jelić (2010)
Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 21 Suppl 5
M. Telli, R. Witteles, G. Fisher, S. Srinivas (2008)
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.Annals of oncology : official journal of the European Society for Medical Oncology, 19 9
K. Öberg (2004)
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms)Acta Oncologica, 43
C. Wojtaszek (2000)
Management of chemotherapy-induced stomatitis.Clinical journal of oncology nursing, 4 6
J. Ferlay, D. Parkin, E. Steliarova-Foucher (2010)
Estimates of cancer incidence and mortality in Europe in 2008.European journal of cancer, 46 4
N. Gardner (2009)
Targeting the mTOR pathway in neuroendocrine tumors.Clinical journal of oncology nursing, 13 5
C. Ferté, A. Paci, M. Zizi, D. Gonzales, A. Goubar, C. Gomez-Roca, C. Massard, T. Sahmoud, F. André, J. Soria (2011)
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.European journal of cancer, 47 15
N. Bhojani, C. Jeldres, J. Patard, P. Perrotte, N. Suardi, G. Hutterer, F. Patenaude, S. Oudard, P. Karakiewicz (2008)
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.European urology, 53 5
Nancy Gardner-Roehnelt (2012)
Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects.Clinical journal of oncology nursing, 16 1
M. Oliveira, Fabiana Martins, Qian Wang, S. Sonis, G. Demetri, S. George, J. Butrynski, N. Treister (2011)
Clinical presentation and management of mTOR inhibitor-associated stomatitis.Oral oncology, 47 10
Anita Schwandt, Laura Wood, B. Rini, R. Dreicer (2009)
Management of side effects associated with sunitinib therapy for patients with renal cell carcinomaOncoTargets and therapy, 2
M. Jf, R. RodriguezZarauz, C. UguetdeResayre, B. Jm (1995)
Diagnosis, treatment and follow-up of H.P.V.-C.I.N.European Journal of Gynaecological Oncology, 16
I. Modlin, S. Moss, D. Chung, R. Jensen, E. Snyderwine (2008)
Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.Journal of the National Cancer Institute, 100 18
G. Lorenzo, C. Porta, J. Bellmunt, C. Sternberg, Z. Kirkali, M. Staehler, S. Joniau, F. Montorsi, C. Buonerba (2011)
Toxicities of targeted therapy and their management in kidney cancer.European urology, 59 4
M. Pavel, J. Hainsworth, E. Baudin, M. Peeters, D. Hörsch, R. Winkler, J. Klimovsky, D. Lebwohl, V. Jehl, E. Wolin, K. Öberg, E. Cutsem, James Yao (2011)
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyThe Lancet, 378
J. Hartmann, L. Kanz (2008)
Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition.Archives of dermatology, 144 11
M. Anlauf (2011)
Neuroendocrine Neoplasms of the Gastroenteropancreatic System: Pathology and ClassificationHormone and Metabolic Research, 43
C. Grande, D. Haller (2009)
Gastrointestinal stromal tumors and neuroendocrine tumors.Seminars in oncology nursing, 25 1
D. O’Toole, A. Grossman, D. Gross, G. Fave, J. Barkmanova, J. O'Connor, U. Pape, U. Plöckinger (2009)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical MarkersNeuroendocrinology, 90
A. Khakoo, Christos Kassiotis, N. Tannir, J. Plana, M. Halushka, Courtney Bickford, J. Trent, J. Champion, J. Durand, D. Lenihan (2008)
Heart failure associated with sunitinib malateCancer, 112
D. White, P. Camus, M. Endo, B. Escudier, E. Calvo, H. Akaza, H. Uemura, E. Kpamegan, A. Kay, M. Robson, A. Ravaud, R. Motzer (2010)
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.American journal of respiratory and critical care medicine, 182 3
J. Kovarik, D. Beyer, R. Schmouder (2006)
Everolimus drug interactions: application of a classification system for clinical decision makingBiopharmaceutics & Drug Disposition, 27
E. Raymond, P. Hammel, C. Dreyer, Christian Maatescu, O. Hentic, P. Ruszniewski, S. Faivre (2012)
Sunitinib in pancreatic neuroendocrine tumorsTargeted Oncology, 7
W. Burns, B. Edil (2012)
Neuroendocrine Pancreatic Tumors: Guidelines for Management and UpdateCurrent Treatment Options in Oncology, 13
R. Cohen, S. Oudard (2012)
Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicitiesInvestigational New Drugs, 30
A. Templeton, M. Brändle, T. Cerny, S. Gillessen (2007)
Remission of diabetes while on sunitinib treatment for renal cell carcinoma.Annals of oncology : official journal of the European Society for Medical Oncology, 19 4
T. Eisen, C. Sternberg, C. Robert, P. Mulders, L. Pyle, S. Zbinden, H. Izzedine, B. Escudier (2012)
Targeted therapies for renal cell carcinoma: review of adverse event management strategies.Journal of the National Cancer Institute, 104 2
C. Kollmannsberger, G. Bjarnason, P. Burnett, P. Creel, Mellar Davis, N. Dawson, D. Feldman, S. George, J. Hershman, T. Lechner, A. Potter, E. Raymond, N. Treister, L. Wood, Shenhong Wu, R. Bukowski (2011)
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.The oncologist, 16 5
M. Kulke, Johanna Bendell, Larry Kvols, J. Picus, Rodney Pommier, James Yao (2011)
Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine TumorsJournal of Hematology & Oncology, 4
Antonio Pérez, S. Jansen-Chaparro, I. Saigi, M. Bernal-López, I. Miñambres, R. Gómez-Huelgas (2014)
Glucocorticoid‐induced hyperglycemia (糖皮质激素诱导的高血糖)Journal of Diabetes, 6
A. Teule, O. Casanovas (2012)
Relevance of angiogenesis in neuroendocrine tumorsTargeted Oncology, 7
C. Bouvier (2003)
Nurse developments in neuroendocrine tumour management.Endocrine-related cancer, 10 4
A. Ravaud (2011)
Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.The oncologist, 16 Suppl 2
M. Kulke, A. Benson, E. Bergsland, J. Berlin, L. Blaszkowsky, M. Choti, O. Clark, G. Doherty, James Eason, L. Emerson, P. Engstrom, W. Goldner, M. Heslin, F. Kandeel, P. Kunz, B. Kuvshinoff, J. Moley, V. Pillarisetty, L. Saltz, D. Schteingart, M. Shah, S. Shibata, J. Strosberg, J. Vauthey, R. White, James Yao, Deborah Freedman-Cass, Mary Dwyer (2012)
Neuroendocrine tumors.Journal of the National Comprehensive Cancer Network : JNCCN, 10 6
D. Klimstra, I. Modlin, D. Coppola, R. Lloyd, S. Suster (2010)
The Pathologic Classification of Neuroendocrine Tumors: A Review of Nomenclature, Grading, and Staging SystemsPancreas, 39
E. Baudin, E. Wolin, D. Castellano, G. Kaltsas, J. Lebrec, Z. Tsuchihashi, J. Klimovsky, S. Saletan, J. Yao, D. Gross (2011)
Effect of everolimus plus octreotide LAR treatment on chromogranin A and 5-hydroxyindoleacetic acid levels in patients with advanced neuroendocrine tumors: Phase III RADIANT-2 study results.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
A. Rinke, H. Müller, C. Schade-Brittinger, K. Klose, P. Barth, M. Wied, C. Mayer, B. Aminossadati, U. Pape, M. Bläker, J. Harder, C. Arnold, T. Gress, R. Arnold (2009)
Placebo-Controlled , Double-Blind , Prospective , Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors : A Report From the PROMID Study Group
G. Blumenthal, P. Cortazar, Jenny Zhang, Shenghui Tang, R. Sridhara, A. Murgo, R. Justice, R. Pazdur (2012)
FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.The oncologist, 17 8
A. Rinke, H. Müller, C. Schade-Brittinger, K. Klose, P. Barth, M. Wied, C. Mayer, B. Aminossadati, U. Pape, M. Bläker, J. Harder, C. Arnold, T. Gress, R. Arnold (2009)
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 28
C. Jacobs (2009)
Neuroendocrine tumors: nursing implications for oral targeted agents and patient management: Part II.Clinical journal of oncology nursing, 13 2
C. Boers-Doets, J. Epstein, J. Raber-Durlacher, J. Ouwerkerk, R. Logan, J. Brakenhoff, M. Lacouture, H. Gelderblom (2012)
Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review.The oncologist, 17 1
D. Nathan (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care, 32
N. Mendelsohn, Y. Messinger, A. Rosenberg, P. Kishnani (2009)
Glycemic Control in Patients with Insulinoma Treated with Everolimus
J. Rodriguez-Pascual, E. Cheng, P. Maroto, I. Durán (2010)
Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinomaAnti-Cancer Drugs, 21
Dariush Mokhtari, N. Welsh (2010)
Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.Clinical science, 118 4
Gregory Ong, D. Henley, D. Hurley, J. Turner, P. Claringbold, P. Fegan (2010)
Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma.European journal of endocrinology, 162 5
James Yao, M. Shah, Tetsuhide Ito, C. Bohas, E. Wolin, E. Cutsem, T. Hobday, T. Okusaka, J. Capdevila, E. Vries, P. Tomassetti, M. Pavel, S. Hoosen, T. Haas, J. Lincy, D. Lebwohl, K. Öberg (2011)
Everolimus for advanced pancreatic neuroendocrine tumors.The New England journal of medicine, 364 6
T. Chu, M. Rupnick, R. Kerkela, S. Dallabrida, D. Zurakowski, L. Nguyen, Kathleen Woulfe, Elke Pravda, F. Cassiola, J. Desai, S. George, David Harris, Nesreen Ismail, Jey-Hsin Chen, F. Schoen, A. Abbeele, G. Demetri, T. Force, M. Chen, J. Morgan (2007)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 370
James Yao, Manal Hassan, A. Phan, Cecile Dagohoy, C. Leary, J. Mares, E. Abdalla, J. Fleming, J. Vauthey, A. Rashid, Douglas Evans (2008)
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 18
A. Vinik, E. Woltering, R. Warner, M. Caplin, T. O'Dorisio, G. Wiseman, D. Coppola, V. Go (2010)
NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine TumorPancreas, 39
Y. Balagula, A. Rosen, B. Tan, K. Busam, M. Pulitzer, R. Motzer, D. Feldman, J. Konner, D. Reidy‐Lagunes, P. Myskowski, M. Lacouture (2012)
Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitorsCancer, 118
A. Jemal, R. Siegel, Jiaquan Xu, Elizabeth Ward (2010)
Cancer Statistics, 2010CA: A Cancer Journal for Clinicians, 60
V. Grünwald, D. Kalanovic, A. Merseburger (2010)
Management of sunitinib-related adverse events: an evidence- and expert-based consensus approachWorld Journal of Urology, 28
M. Falconi, D. Bartsch, B. Eriksson, G. Klöppel, J. Lopes, J. O'Connor, R. Salazar, B. Taal, M. Vullierme, D. O’Toole (2011)
ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning TumorsNeuroendocrinology, 95
E. Raymond, L. Dahan, J. Raoul, Y. Bang, I. Borbath, C. Lombard-Bohas, J. Valle, P. Metrakos, Denis Smith, A. Vinik, Jen‐Shi Chen, D. Hörsch, P. Hammel, B. Wiedenmann, E. Cutsem, S. Patyna, D. Lu, C. Blanckmeister, R. Chao, P. Ruszniewski (2011)
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.The New England journal of medicine, 364 6
Guadalupe Aparicio-Gallego, Moisés Blanco, Angélica Figueroa, R. García-Campelo, M. Valladares-Ayerbes, E. Grande-Pulido, L. Antón-Aparicio (2011)
New Insights into Molecular Mechanisms of Sunitinib-Associated Side EffectsMolecular Cancer Therapeutics, 10
Kun-Ying Tsai, Chih‐hsun Yang, T. Kuo, H. Hong, J. Chang (2006)
Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 36
James Yao, A. Phan, V. Jehl, G. Shah, F. Meric-Bernstam (2013)
Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience.Cancer research, 73 5
(1992)
[Neuroendocrine tumors].La Revue du praticien, 42 7
Together with the use of novel oral targeted therapies, a multidisciplinary approach can be used to effectively treat patients with advanced pancreatic neuroendocrine tumours (pNETs). Here we review the integration of the oncology nurse to the newly developed oral treatment setting for patients with pNETs. From the outset, the nurse must be involved in various processes, including performance of baseline assessments (e.g. blood pathology, cardiac and lung function testing, patient history) and general medical observations, treatment administration, dietary guidance, evaluation of comorbidities, and review of concomitant medications. Patient education and establishment of a strong partnership in care before the start of pNET therapy ultimately increase treatment adherence and reduce potential toxicities. Regular review of general patient status and disease progression and continuous monitoring of adverse events also help enhance treatment outcomes and subsequently improve quality of life. Nurses’ knowledge of agent-specific toxicities and prompt, proactive management is a critical aspect of care. In essence, as the pNET treatment landscape evolves, the role of the healthcare professional in overall patient care must shift accordingly.
Therapeutic Advances in Medical Oncology – SAGE
Published: Aug 23, 2013
Keywords: pancreatic neuroendocrine tumours,patient management,targeted therapy,treatment
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.